Innovative Sensor Technology

Improving Patient Outcomes

Clinical Solution

Welcome to EnteraSense

EnteraSense is developing an innovative sensor technology to detect and monitor Upper Gastrointestinal Bleeding (UGIB). The company has licensed the technology from Brigham and Women’s Hospital and Harvard Medical School and has augmented the Intellectual Property portfolio with further development of the technology.

The sensor is contained within a capsule which is ingested in the same way as existing capsule products in the market today. The optical-based sensor acquires data from the environment during its transit along the Gastrointestinal tract. The data is then processed by an algorithm to determine if blood is present and sends a signal to an external monitor located near the patient. This new technology will significantly enhance the diagnostic capabilities for GI physicians.

EnteraSense will initially target patients that are at high risk of re-bleed and required prolonged monitoring before been discharged. The product will reduce the number of unnecessary endoscopies currently performed in this patient group, delivering benefits to patients and hospitals.

Who Are EnteraSense

EnteraSense Limited is a medical device sensor diagnostic company founded in 2015 by Donal Devery, Dr. Chris Thompson of Brigham and Women’s Hospital/Harvard Medical School and Dr. Marvin Ryou of Brigham and Women’s Hospital in the United States. The company is based in Galway, Ireland and has a licensed technology agreement from Brigham and Women’s Hospital/Harvard Medical School which enables the company to develop devices for diagnosing and monitoring Upper Gastric Bleeds.

The team has vast experience and have a proven track record in innovating technologies and bringing commercially viable products to market.

Team

News

Irish medtech startup gets €2.5m grant boost

January 8th, 2019|

Courtesy Dearbhail McDonald - Irish Independent Jan 07, 2019 An Irish medtech startup that has developed a capsule that can detect bleeding in the gastrointestinal tract has received backing from the European Union [...]

Get In Touch

We are always open to talk more about our product, healthcare and the marketplace – drop us a line.